Share This:
https://ntp.niehs.nih.gov/go/9548

Target Organs and Levels of Evidence for TR-434

Toxicology and Carcinogenesis Studies of 1,3-Butadiene (CASRN 106-99-0) in B6C3F1 Mice (Inhalation Studies)

Chemical (Study Title)
CASRN
Peer Review DatePrimary UsesRoute/Exposure LevelsStudy Laboratory
1,3-Butadiene
106-99-0
11/21/1991Chemical intermediate. Manufacture of synthetic rubber and of thermoplastic resins. Produced from petroleum gases (Merck 1989). Associated with tobacco: reported either as a natural component of tobacco, pyrolysis product (in tobacco smoke), or additive for one or more types of tobacco products.Inhalation
0, 6.25, 20, 62.5, 200, 625 PPM/50 PER GROUP
Battelle Northwest Laboratory

Levels of Evidence

Male Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Hematopoietic System: LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50
  • Vascular System (Heart): HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50
  • Liver: ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50
  • Harderian Gland: ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50
  • Preputial Gland: CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50
  • Kidney Tubular Cell: ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50
  • Brain: (STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50
May Have Been Related
  • Intestines: CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73
  • Zymbal Gland: (STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50
Non-Neoplastic Lesions
  • BONE MARROW: ATROPHY
  • HEART: ENDOTHELIAL HYPERPLASIA, MINERALIZATION; (STOP STUDY) ENDOTHELIAL HYPERPLASIA, MINERALIZATION
  • LUNG: ALVEOLAR EPITHELIAL HYPERPLASIA; (STOP STUDY) ALVEOLAR EPITHELIAL HYPERPLASIA
  • FORESTOMACH: EPITHELIAL HYPERPLASIA; (STOP STUDY) EPITHELIAL HYPERPLASIA
  • HARDERIAN GLAND: HYPERPLASIA; (STOP STUDY) HYPERPLASIA
  • TESTICLE: ATROPHY; (STOP STUDY) ATROPHY
Female Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Hematopoietic System: LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80
  • Vascular System (Heart): HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78
  • Forestomach: SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80
  • Liver: ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80
  • Harderian Gland: ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80
  • Ovary: BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79
  • Mammary Gland: ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80
May Have Been Related
  • Kidney Tubular Cell: ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80
  • Subcutaneous Tissue: NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80
  • Zymbal Gland: ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80
Non-Neoplastic Lesions
  • BONE MARROW: ATROPHY
  • HEART: ENDOTHELIAL HYPERPLASIA; MINERALIZATION
  • LUNG: ALVEOLAR EPITHELIAL HYPERPLASIA
  • FORESTOMACH: EPITHELIAL HYPERPLASIA
  • LIVER: FOCI
  • HARDERIAN GLAND: HYPERPLASIA
  • OVARY: ANGIECTASIS; GRANULOSA CELL HYPERPLASIA; GERMINAL EPITHELIAL HYPERPLASIA; ATROPHY
  • UTERUS: ATROPHY